Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction in a Young Female with Idiopathic Thrombocytopenic Purpura: A Case Report and Review by Yildiz, Ahmet et al.
Hindawi Publishing Corporation
Case Reports in Medicine
Volume 2010, Article ID 854682, 4 pages
doi:10.1155/2010/854682
Case Report
Primary Percutaneous Coronary Intervention for Acute
Myocardial InfarctioninaYoung FemalewithIdiopathic
ThrombocytopenicPurpura: A Case Report and Review
Ahmet Yildiz,Ugur Coskun, Ozlem EsenBatukan, andKudretKeskin
Institute of Cardiology, Istanbul University, Adıvar cad. 34096 Haseki, Istanbul, Turkey
Correspondence should be addressed to Ahmet Yildiz, drayildiz@yahoo.com
Received 16 December 2009; Revised 25 January 2010; Accepted 23 February 2010
Academic Editor: Robert Soufer
Copyright © 2010 Ahmet Yildiz et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A 23-year-old female with the diagnosis of idiopathic thrombocytopenic purpura (ITP) was admitted to our hospital with severe
chest pain. The electrocardiogram (ECG) revealed acute anterior myocardial infarction. She underwent an immediate cardiac
catheterization. An occluded left anterior descending (LAD) was detected by coronary angiography. Reperfusion was performed
successfully by angioplasty and stenting with optimal distal ﬂow without any complications. In this report we discussed the
management strategies of acute myocardial infarction (AMI) in a patient with ITP.
1.Introduction
Idiopathic thrombocytopenic purpura (ITP) is an autoim-
mune disorder characterized by a low platelet count and
mucocutaneous bleeding [1]. Since the prevalence of ITP
is 9.5 per 100000 persons, acute myocardial infarction
(AMI) patients with ITP are seen very rare [2–4]. Throm-
bolytic therapy is contraindicated in ITP patient with AMI.
However, a few cases of primary percutaneous coronary
intervention (PCI) for AMIs have been reported in patients
with ITP [3–7].
2.CaseReport
A 23-year-old female was admitted to our hospital with
severe chest pain. The patient had been diagnosed with
chronic ITP 4 years ago. She was treated with steroids which
had been stopped one year previously. Two weeks prior to
admission, she was started on a course of steroids due to a
low platelet count.
On admission, the electrocardiogram (ECG) revealed a
regular sinus rhythm with a rate of 80/min and ST segment
elevations in V2–V5 and aVL (Figure 1). The platelet count
was 35000/µL. The patient was immediately transferred to
the catheterization laboratory. Angiography revealed total
occlusion of the left anterior descending artery (LAD;
Figure 2). The circumﬂex and right coronary arteries were
normal. Then, 600mg of clopidogrel was loaded and weight-
adjusted UFH (60U/kg) was administered intravenously just
before the PCI. After crossing the total occlusion with a
0.014inch high-torque ﬂoppy wire the lesion was dilated
with a 2.0 × 20mm balloon (Ma’slaJut, Asahi Intecc, Japan)
with an inﬂation pressure of 12atm. After pre-dilation, a
3.0×20mmMi-JAZZstentwasimplantedat12atmpressure
(bare metal; Millimed, Raskijde, Denmark) into the LAD.
Subsequent angiography demonstrated thrombolysis in
myocardial infarction (TIMI) grade III ﬂow and optimal
myocardial contrast blush (Figure 2). After restoration of
blood ﬂow, the chest pain resolved and the ST segment
elevations in the ECG regressed within 1 hour. The activated
partial thromboplastin time was 155 seconds. Following
the procedure, the patient was transferred to the intensive
care unit (ICU) and treated with aspirin (300mg/day),
clopidogrel (75mg/day), metoprolol (50mg/day), ramipril
(2.5mg/day), and atorvastatin (40mg/day); heparin was not
administered. The sheath introducer was removed from the
right femoral artery after the PCI, and hand compression













Figure 1: Electrocardiogram presents ST segment elevation in leads of V2–V5 and aVL.
achieve complete hemostasis. We noted ecchymoses around
the puncture site of the right femoral artery. No other bleed-
ing complications occurred. The patient was subsequently
monitored in the ICU for 48 hours and discharged after 5
days without any complications related to the myocardial
infarction and the PCI.
3. Discussion
ITP is characterized by the presence of antiplatelet antibod-
ies,immuneplateletdestruction,andalowplateletcount[8].
An AMI is rarely experienced in patients with ITP [2]. Only
ﬁve cases of primary PCI for AMI in patients with ITP have
beenreportedintheliterature([3–7];Table 1).Themeanage
of these 5 patients was 65 years; therefore, our patient is the
youngest patient to be reported in the literature. ITP occurs
with a higher incidence (3 : 1) among female adult patients
[1].
Fuchi et al. [3] reported a 72-year-old female diagnosed
with ITP in 1999. She had never smoked, and there was no
history of ischemic heart disease in her family. She had a
history of hyperlipidemia. Coronary angiography revealed
total occlusion of the LAD. Although PCI was successfully
performed for stenosis in the proximal LAD, the condition
of the patient was complicated by a reinfarction. A large
hematoma was observed around the femoral artery puncture
site. For this reason, immunoglobulin and methylpred-
nisolone were administered intravenously.
Kikuchi et al. reported a case of acute anterior myocar-
dial infarction in a 68-year-old woman with hypertension,
hyperlipidemia, and diabetes mellitus and a platelet count
of 22,000/µL[ 4]. PCI was performed and there was no
bleeding tendency with heparin infusion and ticlopidine
hydrochloride.
Anothercaseofcoronaryinvolvementpresentingwithan
inferior myocardial infarctioninvolved a 47-year-old woman
with chronic ITP. Heparin was administered during PCI
only, and combined antiplatelet therapy (aspirin 200mg
and clopidogrel 75mg) was performed. No major bleeding
complications occurred [5].
Fong et al. [6] reported a 71-year-old ITP patient who
presented with acute coronary syndrome. Cardiac catheter-
ization was performed through the radial artery with the
administration of immunoglobulin premedication. This was
followed by clopidogrel treatment for 7 weeks without major
bleeding complications. Gracia et al. [7]r e c e n t l yr e p o r t e da
young man who had total LAD occlusion and was treated
successfully by primary PCI under cover of unfractionated
heparin prophylaxis and anti-aggregation with clopidogrel
and ASA.
If patient with ITP has coronary artery disease, concomi-
tant inﬂuence of traditional coronary risk factors should
be considered. In our case, the patient did not have
any known coronary artery risk factors, such as a family
history of coronary artery disease, hypercholesterolemia,
hypertension, diabetes, or smoking. She also had not had
arteritis, trauma, embolization (factor V, factor VIII, and
total homocysteine level), dissection, spasm, or congenital
anomalies. We thought that drug use (steroids) was the most
probable etiology in our case. Steroids are known to induce
metabolic changes, as well as a hypercoagulable state [9].
Another hypothesis is that the pathogenesis of myocar-
dial infarction in thrombocytopenic patients with ITP may
result from endothelial damage induced by autoantibodies
directed against antigens, which are present in both platelets
and coronary endothelial cells [10].
Transradial approach of coronary angiography and
angioplasty has become a good alternative to the femoralCase Reports in Medicine 3
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Figure 2: Coronary angiography of the left coronary artery. (a) Total obstruction in the proximal left anterior descending artery (LAD). (b)
Dilation. (c) After balloon angioplasty. (d) After stent implantation, PCI was successful.
Table 1: Case reports of AMI with ITP treated with primary PCI.
Name Age Platelet count/µL Chronic ITP Approach Major Bleeding IVIG Steroid Under treatment
Fuchi et al. [3] 72/F 59000 Yes Femoral Yes Yes Yes No
Kikuchi et al. [4] 68/F 22000 No Femoral No No No No
Kim et al. [5] 47/F 21000 Yes Femoral No Yes Yes No
Fong et al. [6] 71/F 30000 Yes Radial No Yes No No
Gracia et al. [7] 37/M 39000 Yes Femoral No No No No
Current case 23/F 35000 Yes Femoral No No No Steroids
ITP: idiopathic thrombocytopenic purpura; IVIG: intravenous immunoglobulin.
approachinallpatientsduetothelowrateofaccesssitecom-
plications, improved patient comfort, and early ambulation.
This approach is particularly applicable to patients receiving
anticoagulation treatment or thrombolytics due to the ease
of compressing the puncture site.
The other important issue for ITP patients is control of
hemostasis. Fuchi et al. [3] reported that large hematomas
were observed around the puncture sites. Sheath introducers
from the radial artery can be removed after the procedure,
followed by compression to achieve complete hemostasis
of the puncture sites. After the procedure, intravenous
immunoglobulin can be used to prevent bleeding complica-
tions. However, when intravenous immunoglobulin therapy
is required for a patient with ITP for thrombocytopenia,
careful attention must be paid for a rapid rise in the platelet
count, which may induce myocardial infarction or stroke,
particularly in the elderly patients and in patients with
coronary risk factors. There is no recommended dose of4 Case Reports in Medicine
heparin in such cases. However, a weight-adjusted dose
can be used. Caution must be exercised in low-molecular-
weight heparin because of its unmonitored and long-term
eﬀects. Consequently, a double loading dose of clopidogrel
(600mg) combined with anti-platelet therapy (aspirin plus
clopidogrel, 75mg) should be prescribed.
The choice of implanting a bare metal stent was
undertaken by the operator due to desire avoid late stent
thrombosis. However there is no data on the safety of drug
eluting stents in circumstances like ITP [11].
This case is the ﬁrst report of a young female with
ITP presenting with an AMI without any cardiovascular
risk factors treated with primary PCI. In conclusion, the
following key issues arose from our case and review of
the literature: Primary PCI is a useful, safe, and feasi-
ble therapeutic strategy in acute ST elevation myocardial
infarction. Careful attention must be paid to hemostasis,
therefore vessels do not injure at the time of puncture.
Additionally,removingthesheathearlierandmonitoringthe
coagulation may lead to achieve successful hemostasis. The
transradialapproachisparticularlyapplicableduetotheease
ofcompressingthepuncturesite.Attentionmustalsobepaid
to intravenous immunoglobulin therapy in order to prevent
bleeding complications. Low dose heparin (unfractionated)
can be used and combined antiplatelet therapy (aspirin plus
clopidogrel) should be continued.
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